Exchange: NYSE·Updated 07:30 PM EDT

COR News

News
all
press releases
Here's Why Cencora (COR) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks
More News
$1000 Invested In Cencora 10 Years Ago Would Be Worth This Much Today
Cencora (NYSE:COR) has outperformed the market over the past 10 years by 6.79% on an annualized basis producing an average annual return of 20.35%. Currently, Cencora has a market capitalization of $61.36 billion.read more...
Benzinga
CAH Gains More Than 29% in 4 Months: Will the Uptrend Continue?
Cardinal Health's 29% rally reflects stronger specialty growth, MSO expansion and higher-margin assets, but cost pressures could test the uptrend.
Zacks
Here's Why Cencora (COR) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
Why Cencora (COR) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks
Here's Why You Should Retain Cencora Stock in Your Portfolio for Now
Cencora's specialty momentum, OneOncology growth and GLP-1 volumes offer upside, but drug-price cuts and MWI risks cloud its outlook.
Zacks
Cencora (COR) Up 3.8% Since Last Earnings Report: Can It Continue?
Cencora (COR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Cencora Launches Cell and Gene Therapy Enablement for Health Systems
COR launches CGT Enablement to help health systems build and scale cell and gene therapy programs with financial, operational and access support.
Zacks
Cencora Raises 2026 EPS Outlook as Specialty Businesses Strengthen
Cencora raised its fiscal 2026 EPS outlook as specialty businesses fueled stronger profit growth despite mix, pricing and financing pressures.
Zacks
Artisan Sold Cencora (COR) as Earnings Momentum Slowed
Artisan Sold?Cencora?(COR) as Earnings Momentum Slowed...
Yahoo! Finance: News

Advertisement|Remove ads.